ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1681

4-Week Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor Filgotinib (GLPG0634) Changes Lipid Profile with a Preferential Increase in HDL

René Galien1, Pille Harrison2, Reginald Brys2, Annegret Van der Aa2, Gerben van 't Klooster2 and Chantal Tasset2, 1Galapagos SASU, Romainville, France, 2Galapagos NV, Mechelen, Belgium

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biomarkers, Cholesterol and rheumatoid arthritis (RA), Janus kinase (JAK)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 9, 2015

Session Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Patients with active rheumatoid arthritis (RA) present low levels of lipids – total cholesterol (TC), low density lipoprotein-cholesterol (LDL-c), high density lipoprotein-cholesterol (HDL-c) and triglycerides (TG) – and yet are at a higher risk of cardiovascular disease. RA therapies may modulate lipid levels, presumably because of their anti-inflammatory effects, but some treatments preferentially increase LDL-c, thereby worsening the atherogenic index. We previously reported that 4-week treatment with the JAK1 selective inhibitor filgotinib (GLPG0634), showed a different profile with little effect on LDL-c and a dose-dependent increase in HDL-c. The current study further characterizes the lipid profile of RA patients after filgotinib treatment.

Methods:

RA patients (n=91) with insufficient response to MTX were randomized to receive placebo or 30, 75, 150 or 300 mg filgotinib once-daily orally for 4 weeks as add-on to MTX in a double-blind phase 2a study. Blood was sampled pre-dose and on the last day of treatment. Plasma PCSK9, ApoC-II, ApoC-III, SAA, and CETP concentrations were measured using ELISA kits. Plasma CETP and LCAT activities were determined using a commercial assay from Roar Biomedical. Plasma cholesterol (total and non-HDL-cholesterol), HDL-c, TG, ApoA-I and ApoB were measured using assays available from Diasys. CETP expression in white blood cells (WBC) was measured using qPCR.

Results:

HDL-c increased after treatment with 75, 150 and 300 mg of filgotinib, whereas TC and non-HDL-c increased in plasma only with 300mg dose, compared to baseline.

TREATMENT

TC

non-HDL-c

HDL-c

TC/HDL-c

PLACEBO

110 +/- 7

110 +/- 8

116 +/- 10

98 +/- 5

30 mg

126 +/- 16

131 +/- 20

107 +/- 5

119 +/- 14

75 mg

105 +/- 5

103 +/- 7

114 +/- 4 ***

93 +/- 4

150 mg

99 +/- 5

96 +/- 5

111 +/- 5 *

90 +/- 4 **

300mg

119 +/- 3 ***

113 +/- 3 ***

146 +/- 7 ***

85 +/- 5 ***

Percent change from baseline in biomarkers after 4 weeks of filgotinib treatment (Mean +/- SEM – T-test *: p<0.05; **: p<0.01; ***: p<0.001, compared to baseline)

TC/HDL-c ratio (atherogenic index) decreased after 4 weeks of filgotinib treatment . Plasma concentrations of ApoA-I, ApoB, ApoC-II and ApoC-III also indicated a preferential increase in HDL-c over LDL-c, with an increase in ApoA-I, ApoC-II and ApoC-III and no change in ApoB concentrations, resulting in a decrease in ApoB/ApoA-I ratio. CETP gene expression in circulating WBC as well as protein concentration and enzyme activity in plasma decreased after treatment. LCAT activity and paraoxonase-1 (PON-1) levels increased with filgotinib treatment. There was no change in plasma concentration of PCSK9.

Conclusion:

These early data show that 4 weeks of treatment with filgotinib changed the lipid profile in RA patients, with a preferential increase in HDL-c.  As a consequence, the atherogenic index in RA patients improved with doses of 150 and 300 mg once daily. This correlated with changes in HDL-c proteins and enzymes involved in HDL-c homeostasis such as ApoA-1, PON-1, LCAT and CETP, but not in those linked to LDL-c (ApoB, PCSK9).  Further longer-term studies are needed to confirm these findings and their cardiovascular relevance.


Disclosure: R. Galien, Galapagos SASU, 3,AbbVie, 2; P. Harrison, Galapagos NV, 3,AbbVie, 2; R. Brys, Galapagos NV, 3,AbbVie, 2; A. Van der Aa, Galapagos NV, 3,AbbVie, 2; G. van 't Klooster, Galapagos NV, 3,Abboie, 2; C. Tasset, Galapagos NV, 3,AbbVie, 2.

To cite this abstract in AMA style:

Galien R, Harrison P, Brys R, Van der Aa A, van 't Klooster G, Tasset C. 4-Week Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor Filgotinib (GLPG0634) Changes Lipid Profile with a Preferential Increase in HDL [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/4-week-treatment-of-rheumatoid-arthritis-patients-with-the-jak1-selective-inhibitor-filgotinib-glpg0634-changes-lipid-profile-with-a-preferential-increase-in-hdl/. Accessed February 24, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/4-week-treatment-of-rheumatoid-arthritis-patients-with-the-jak1-selective-inhibitor-filgotinib-glpg0634-changes-lipid-profile-with-a-preferential-increase-in-hdl/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.